Business
Revolutionizing Mental Health: AI-Powered Facial Screening Technology Set for Clinical Trials
Synbio International Inc. secures rights to conduct clinical trials for AI-powered depression screening technology (NIMS: Non-invasive Mental Screening). NIMS is a fast, highly accurate and cost-effective method for detecting depressive symptoms through ...
About this update from Synbio International Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Synbio International Inc. secures rights to conduct clinical trials for AI-powered depression screening technology (NIMS: Non-invasive Mental Screening).","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"NIMS is a fast, highly accurate and cost-effective method for detecting depressive symptoms through facial analysis.","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"NIMS software is integrated into an app, that analyzes facial features from high-definition images captured by a mobile phone or desktop device.","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"The clinical trials will assess NIMS's accuracy, reliability, and scalability for widespread use.","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Successful trial results will support regulatory approval, paving the way for Synbio to integrate NIMS into clinical and corporate settings.","length":140,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":654,"olType":false},{"type":"text","content":"NEW YORK CITY, NY / ACCESS Newswire / February 25, 2025 / Synbio International Inc. (Synbio) is pleased to announce that it will conduct clinical trials to validate innovative AI-powered facial analysis software for non-invasive medical screening (NIMS) for depressive symptoms. FacialDx Inc. (FacialDx), an innovative AI-digital health company, developed this cutting-edge technology with the potential to revolutionize the early identification of mental health conditions.","length":474,"tagName":"p"},{"type":"text","content":"Under a Clinical Trial License Agreement with FacialDx, Synbio will undertake trials to validate NIMS's accuracy, reliability, and scalability. The first trial will involve a retrospective feasibility study. If this trial is deemed a success, a larger prospective validation trial will follow. Upon successful validation, Synbio will secure licensing rights to commercialize NIMS into clinical and corporate settings.","length":421,"tagName":"p"},{"type":"text","content":"The NIMS Software","length":17,"tagName":"p"},{"type":"text","content":"NIMS employs advanced AI and machine learning algorithms, integrated into an app, that analyzes facial features from high-definition images captured by mobile phones or desktop devices. This technology provides instant...